--- title: "MacroGenics, Inc. (NASDAQ:MGNX) Short Interest Down 22.5% in April" type: "News" locale: "en" url: "https://longbridge.com/en/news/284601403.md" description: "MacroGenics, Inc. (NASDAQ:MGNX) experienced a 22.5% decline in short interest in April, totaling 2,928,196 shares as of April 15th. Currently, 5.3% of shares are short sold, with a short-interest ratio of 3.0 days based on an average trading volume of 979,052 shares. Analysts have mixed ratings, with Barclays raising the target price to $6.00 and B. Riley upgrading to a buy rating with a target of $9.00. The stock is currently trading at $2.96, down 1.8%, with a market cap of $187.82 million and a negative EPS of -$0.22 for the last quarter." datetime: "2026-04-29T15:01:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284601403.md) - [en](https://longbridge.com/en/news/284601403.md) - [zh-HK](https://longbridge.com/zh-HK/news/284601403.md) --- # MacroGenics, Inc. (NASDAQ:MGNX) Short Interest Down 22.5% in April MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totaling 2,928,196 shares, a drop of 22.5% from the March 31st total of 3,778,755 shares. Based on an average daily trading volume, of 979,052 shares, the days-to-cover ratio is currently 3.0 days. Currently, 5.3% of the shares of the stock are sold short. ## Wall Street Analysts Forecast Growth Several equities analysts have weighed in on MGNX shares. Barclays raised their target price on shares of MacroGenics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Monday, April 20th. B. Riley Financial upgraded MacroGenics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $3.00 to $9.00 in a research report on Friday, April 10th. Zacks Research lowered MacroGenics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 1st. Citigroup reiterated a "market perform" rating on shares of MacroGenics in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised shares of MacroGenics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MacroGenics presently has a consensus rating of "Hold" and an average target price of $5.40. **Check Out Our Latest Research Report on MGNX** ## MacroGenics Stock Down 1.8% Shares of NASDAQ MGNX traded down $0.06 during midday trading on Wednesday, hitting $2.96. The stock had a trading volume of 97,249 shares, compared to its average volume of 1,019,032. The company has a fifty day moving average price of $2.84 and a 200 day moving average price of $2.05. The company has a market capitalization of $187.82 million, a price-to-earnings ratio of -2.53 and a beta of 1.09. MacroGenics has a 1-year low of $1.18 and a 1-year high of $3.88. MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.20. MacroGenics had a negative net margin of 49.91% and a negative return on equity of 120.19%. The firm had revenue of $41.23 million for the quarter, compared to analysts' expectations of $27.81 million. On average, research analysts forecast that MacroGenics will post -1.2 EPS for the current year. ## Hedge Funds Weigh In On MacroGenics A number of institutional investors and hedge funds have recently bought and sold shares of MGNX. Jefferies Financial Group Inc. acquired a new position in shares of MacroGenics during the fourth quarter worth $2,964,000. Renaissance Technologies LLC increased its stake in MacroGenics by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,908,631 shares of the biopharmaceutical company's stock worth $4,683,000 after buying an additional 1,207,408 shares during the period. Marshall Wace LLP lifted its holdings in MacroGenics by 104.0% in the 4th quarter. Marshall Wace LLP now owns 1,284,563 shares of the biopharmaceutical company's stock worth $2,068,000 after buying an additional 655,028 shares in the last quarter. Jane Street Group LLC grew its stake in shares of MacroGenics by 207.7% during the second quarter. Jane Street Group LLC now owns 758,204 shares of the biopharmaceutical company's stock valued at $917,000 after acquiring an additional 511,777 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in shares of MacroGenics in the fourth quarter worth about $780,000. Hedge funds and other institutional investors own 96.89% of the company's stock. ## MacroGenics Company Profile (Get Free Report) MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer. Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies. ## Featured Stories - Five stocks we like better than MacroGenics _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in MacroGenics Right Now? Before you consider MacroGenics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list. While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MGNX.US](https://longbridge.com/en/quote/MGNX.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ONEQ.US](https://longbridge.com/en/quote/ONEQ.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md) - [QQQ.US](https://longbridge.com/en/quote/QQQ.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [ATMP.US](https://longbridge.com/en/quote/ATMP.US.md) - [RILY.US](https://longbridge.com/en/quote/RILY.US.md) - [SMIZ.US](https://longbridge.com/en/quote/SMIZ.US.md) - [QUIZ.US](https://longbridge.com/en/quote/QUIZ.US.md) - [GROZ.US](https://longbridge.com/en/quote/GROZ.US.md) - [NA.US](https://longbridge.com/en/quote/NA.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [000402.CN](https://longbridge.com/en/quote/000402.CN.md) - [RMNI.US](https://longbridge.com/en/quote/RMNI.US.md) - [CLW.AU](https://longbridge.com/en/quote/CLW.AU.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [JCAP.US](https://longbridge.com/en/quote/JCAP.US.md) - [AMPGW.US](https://longbridge.com/en/quote/AMPGW.US.md) - [RNST.US](https://longbridge.com/en/quote/RNST.US.md) - [RNTX.US](https://longbridge.com/en/quote/RNTX.US.md) - [GITS.US](https://longbridge.com/en/quote/GITS.US.md) - [MSLH.UK](https://longbridge.com/en/quote/MSLH.UK.md) - [JMSB.US](https://longbridge.com/en/quote/JMSB.US.md) - [CWK.US](https://longbridge.com/en/quote/CWK.US.md) - [3675.JP](https://longbridge.com/en/quote/3675.JP.md) - [JANT.US](https://longbridge.com/en/quote/JANT.US.md) - [JANZ.US](https://longbridge.com/en/quote/JANZ.US.md) - [AFBI.US](https://longbridge.com/en/quote/AFBI.US.md) - [AAMI.US](https://longbridge.com/en/quote/AAMI.US.md) - [BASC.UK](https://longbridge.com/en/quote/BASC.UK.md) - [RILYL.US](https://longbridge.com/en/quote/RILYL.US.md) - [RILYG.US](https://longbridge.com/en/quote/RILYG.US.md) - [RILYN.US](https://longbridge.com/en/quote/RILYN.US.md) - [RILYK.US](https://longbridge.com/en/quote/RILYK.US.md) - [RILYP.US](https://longbridge.com/en/quote/RILYP.US.md) - [RILYZ.US](https://longbridge.com/en/quote/RILYZ.US.md) - [RILYT.US](https://longbridge.com/en/quote/RILYT.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [CQR.AU](https://longbridge.com/en/quote/CQR.AU.md) - [CHC.AU](https://longbridge.com/en/quote/CHC.AU.md) - [CQE.AU](https://longbridge.com/en/quote/CQE.AU.md) - [AMPGR.US](https://longbridge.com/en/quote/AMPGR.US.md) - [AMPG.US](https://longbridge.com/en/quote/AMPG.US.md) - [AMPGZ.US](https://longbridge.com/en/quote/AMPGZ.US.md) ## Related News & Research - [MacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties](https://longbridge.com/en/news/286310410.md) - [MacroGenics Expands ZYNYZ Royalty Agreement for Added Funding](https://longbridge.com/en/news/285124550.md) - [HC Wainwright Analysts Increase Earnings Estimates for CTMX](https://longbridge.com/en/news/286258226.md) - [Silence Therapeutics (NASDAQ:SLN) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS](https://longbridge.com/en/news/285818628.md) - [ICU Medical director David C. Greenberg disposes 2,424 shares valued at $297,537.84](https://longbridge.com/en/news/286334294.md)